Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Thomas Kipps, MD, PhD
William Wierda, MD, PhD
Fixed-Duration: A Patient-Captivating Standard of Care in CLL
Talha Munir, PhD
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Combination Therapy for CLL: What Evidence Do We Have?
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
MRD Testing to Guide Treatment Considerations in CLL
Risk-Stratification in Newly Diagnosed CLL
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Mutational Testing to Guide Therapy in CLL: Why and When
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Josep Tabernero, MD, PhD
Sara Lonardi, MD
Zev A. Wainberg, MD
Advancements in GU Cancers: Key Data from AUA 2024
Jason Hafron, MD
Carissa Chu. MD
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Javier Cortes, MD, PhD
Komal Jhaveri, MD, FACP
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Jeffrey V. Matous, MD
Donna Catamero, NP
Ajai Chari, MD
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.